Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 11:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 13,736 matching trials from the live ClinicalTrials.gov search.

Filters: Baltimore, Maryland Clear all

Conditions: Mass Balance Recovery
Interventions: [14C]-D-0502; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mitral Valve Prolapse, Left Ventricular Fibrosis, Ventricular Arrhythmias
Interventions: Cardiac Magnetic Resonance Imaging, ZioPatch Monitoring, Myocardial Tissue Biopsy; Procedure · Device
Lead sponsor: Annetine Gelijns; Other
Eligibility: 60 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 11 more

Conditions: Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions: Communication; Other
Lead sponsor: University of Michigan; Other
Eligibility: 1 Year to 80 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 16
States / cities: Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more

Conditions: Schizophrenia
Interventions: Computer Assisted Cognitive Remediation (CACR); Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 3
States / cities: Baltimore, Maryland • Catonsville, Maryland

Conditions: Semen Exposure
Interventions: Not listed
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Baltimore, Maryland • Norfolk, Virginia

Conditions: Health Services Accessibility
Interventions: Survey; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Esophageal Cancer, Gastrointestinal Complications
Interventions: management of therapy complications, quality-of-life assessment; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pelvic Organ Prolapse, Urinary Incontinence, Patient Education
Interventions: Educational Intervention with video; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab; Procedure · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 45
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more

Conditions: Pulmonary Tuberculosis
Interventions: Rifapentine, Isoniazid; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2001
U.S. locations: 20
States / cities: Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more

Conditions: Tobacco Dependence
Interventions: Nicotine Patch, Nicotine Gum; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 13 Years to 17 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Pembrolizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 31
States / cities: Chandler, Arizona • Los Angeles, California • Santa Barbara, California + 19 more

Conditions: Cornelia de Lange Syndrome
Interventions: ABA-based functional analysis and treatment; Behavioral
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 3 Years to 15 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Intermittent Exotropia
Interventions: Eye Patch; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 3 Years to 8 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Berkeley, California + 21 more

Conditions: COVID-19, COVID Long-Haul
Interventions: Magnetic Resonance Imaging, Ultra-High Resolution Computed Tomography (CT) Scan; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease (CKD)
Interventions: Vonsetamig; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 7 more

Conditions: Diarrhea, HIV Infections
Interventions: Crofelemer; Drug
Lead sponsor: Shaman Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Ischemic Stroke
Interventions: Nautilus NeuroWaveTM System; Device
Lead sponsor: Jan Medical, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Prostatic Hyperplasia
Interventions: FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Asthma, Allergy, Allergic Rhinitis, Rhinitis, Allergic, Seasonal
Interventions: Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: CNS Tumor
Interventions: Not listed
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 31
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottdale, Arizona + 28 more

Conditions: Loneliness, Mood
Interventions: AI phone companion; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions: Placebo Oral Tablet, AGB101 220 mg tablet; Drug
Lead sponsor: AgeneBio; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 23
States / cities: Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more

Conditions: Billiary Track Cancer
Interventions: Gemcitabine, Cisplatin, Pembrolizumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Study in Healthy Adult Female Subjects

PRIMARY Ancillary Substudy

NEPTUNE Match Study

Cognitive Remediation for Schizophrenia

Residence Time of Biomarkers of Semen Exposure

A National Survey on the Prevalence and Impact of Multiple Pharmacy Use in Specialty Pharmacy

Plastic Stents Compared With Metal Stents in Treating Patients With Malignant Dysphagia Caused by Esophageal Cancer or Gastroesophageal Junction Cancer

Pelvic Floor Disorder Assessment of Knowledge and Symptoms: an Educational Model in Spanish-Speaking Women

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis

Safety, Tolerability and Efficacy of the Nicotine Patch and Gum for the Treatment of Adolescent Tobacco Dependence

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

Behavioral Assessment and Treatment of Problem Behavior in Children With Cornelia de Lange Syndrome

Full-Time Occlusion Therapy for Intermittent Exotropia in Children

Comprehensive Imaging Exam of Convalesced COVID-19 Patients

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients

Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke

Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects

Treatment of Ragweed-Allergic Asthma With an Immunostimulatory Drug

Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry

BabaCare: Testing a Care Copilot

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers